Brief: Bioretec Says Submitted Additional Information Requested By U.S. FDA For Registration Of Remeos Trauma Screws
Jan 3 (Reuters) - Bioretec Oy BRETEC.HE :
* BIORETEC HAS SUBMITTED ADDITIONAL INFORMATION REQUESTED BY
THE
FDA FOR US REGISTRATION OF REMEOS™ TRAUMA SCREWS, AND THE
ESTIMATED APPROVAL TIMELINE OF APRIL 2023 REMAINS UNCHANGED
* BIORETEC'S ESTIMATE FOR RECEIVAL OF U.S. MARKET
AUTHORIZATION
REMAINS UNCHANGED IN APRIL 2023
Source text for Eikon: ID:nPn4GCGWva
Further company coverage: BRETEC.HE
((reuters.briefs@thomsonreuters.com;))
Recent news on Bioretec Oy
See all newsBrief: Bioretec Initiates Change Negotiations
Brief: Bioretec Gets Marketing Authorization From FDA
Brief: Bioretec Receives FDA 510(K) Clearance For Its Activascrew Cannulated Com Bioabsorbable Compression Screw
Finland's Bioretec H1 revenue rises 12%, loss narrows
Brief: Bioretec Q2 Net Sales EUR 1.1 Million